Technology ID
TAB-3969

Nandrolone 17 Beta-Carbonates

E-Numbers
E-181-2004-0
Lead Inventor
Blye, Richard
Lead IC
NICHD
Co-Inventors
Kim, Hyun
Lee, Min
ICs
NICHD
Applications
Therapeutics
Therapeutic Areas
Reproductive Health
Endocrinology
Development Stages
Clinical Phase I

Summary:

Researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development are highly motivated in seeking licensing and/or collaboration partners for the development and use of androgenic compounds as contraceptives and/or hormonal therapeutics.

Description of Technology:

The available options for male contraceptives are limited. Androgens are administered as part of hormone-based male contraception and have also been used in the treatment of hypogonadism and hormone replacement therapy HRT. Many synthetic androgens require an oil-based delivery vehicle and have limited durations of action.

This technology describes androgenic compounds and pharmaceutical compositions thereof for use in a number of diseases or conditions, most notably as a potential male contraceptive, and as an androgenic agent suppressing the release of hormones such as the luteinizing hormone. Additional potential therapeutic areas include hypogonadism, osteoporosis, and anemia. 
Since 2016, NICHD has been testing the following lead compound as a male contraceptive in Phase I clinical trials:

Safety and pharmacokinetics of oral single-dose, 28 day repeat-dose, and dose escalation study of 11-MNTDC in healthy men have been conducted.  The drug was well tolerated without serious adverse events.  Daily oral dose of 11β-MNTDC for 28 days in healthy men showed markedly suppressed serum gonadotropins and T concentrations without serious adverse effects.  NICHD is planning another Phase I trial to test 11β-MNTDC via intramuscular injection. 

 

Potential Commercial Applications:

  • Male contraceptive
  • Treatment of hormonal diseases

Competitive Advantages:

  • Significant market need for male contraceptive
  • Clinical-stage asset
  • No adverse events in a Phase I dose-escalation study
  • Intramuscular (IM) injection

Request More Info

Licensing Contact:
Gunas, Heather
gunash@mail.nih.gov

Patents

  • US
    Provisional (PRV) 60/650,376
    Filed on 2005-02-04
    Status: Abandoned
  • Patent Cooperation Treaty
    (PCT) PCT/US2006/02436
    Filed on 2006-01-24
    Status: Expired
  • Australia
    National Stage 2006211907
    Filed on 2006-01-24
    Status: Abandoned
  • Canada
    National Stage 2596884
    Filed on 2006-01-24
    Status: Abandoned
  • European Patent
    National Stage 06719336.7
    Filed on 2006-01-24
    Status: Abandoned
  • Japan
    National Stage 2007-554134
    Filed on 2006-01-24
    Status: Abandoned
  • US Patent 7,820,642
    Filed on 2007-08-03
    Status: Issued
  • Germany
    European patent (EP) 06719336.7
    Filed on 2006-01-24
    Status: Abandoned
  • France
    European patent (EP) 06719336.7
    Filed on 2006-01-24
    Status: Abandoned
  • United Kingdom
    European patent (EP) 06719336.7
    Filed on 2006-01-24
    Status: Abandoned

Publications

Collaborations

  • Licensing
  • Collaboration
Date Published